T M Richards1, S A Bhide2, A B Miah1, L Del Rosario1, S Bodla3, K Thway4, D M Gujral1, K P Rooney1, U Schick1, T McGovern1, L Grove1, K L Newbold1, K J Harrington2, C M Nutting5. 1. Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London and Surrey, UK. 2. Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London and Surrey, UK; The Institute of Cancer Research, London, UK. 3. Department of Statistics, Royal Marsden Hospitals NHS Foundation Trust, Sutton, UK. 4. Department of Pathology, Royal Marsden Hospitals NHS Foundation Trust, London, UK. 5. Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London and Surrey, UK. Electronic address: Chris.Nutting@rmh.nhs.uk.
Abstract
AIMS: To determine the clinical outcomes of an intensity-modulated radiotherapy technique for total mucosal irradiation (TM-IMRT) in patients with head and neck carcinoma of unknown primary (HNCUP). MATERIALS AND METHODS: A single-centre prospective phase II trial design was used in two sequential studies to evaluate TM-IMRT for HNCUP. Patients were investigated for primary tumour site using examination under anaesthetic and biopsies, computed tomography ± magnetic resonance imaging (MRI) or 18-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT). Patients received IMRT to the potential primary tumour sites and elective cervical nodes. Concomitant chemotherapy was used in patients who received primary radiotherapy or those with nodal extracapsular extension. RESULTS: Thirty-six patients with HNCUP were recruited; 72% male. Twenty-five patients (69.4%) had p16-positive disease. Two year mucosal and local nodal control rates were 97.1% (95% confidence interval 91.4-100) and 89.8% (78.4-100), respectively. One mucosal primary was detected 7.3 months after TM-IMRT and three patients died from recurrent/metastatic squamous cell carcinoma of the head and neck. Twelve patients (33%) developed grade 3 (Late Effects in Normal Tissue-Subjective, Objective, Management and Analytical; LENT-SOMA) dysphagia with a 1 year enteric tube feeding rate of 2.7%. The high-grade subjective xerostomia rate (LENT-SOMA) at 24 months after IMRT was 15%. CONCLUSIONS: At a median follow-up of 36.1 months, the use of TM-IMRT was associated with good local control. Toxicity was comparable with previously reported TM-IMRT regimens encompassing similar mucosal volumes.
AIMS: To determine the clinical outcomes of an intensity-modulated radiotherapy technique for total mucosal irradiation (TM-IMRT) in patients with head and neck carcinoma of unknown primary (HNCUP). MATERIALS AND METHODS: A single-centre prospective phase II trial design was used in two sequential studies to evaluate TM-IMRT for HNCUP. Patients were investigated for primary tumour site using examination under anaesthetic and biopsies, computed tomography ± magnetic resonance imaging (MRI) or 18-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT). Patients received IMRT to the potential primary tumour sites and elective cervical nodes. Concomitant chemotherapy was used in patients who received primary radiotherapy or those with nodal extracapsular extension. RESULTS: Thirty-six patients with HNCUP were recruited; 72% male. Twenty-five patients (69.4%) had p16-positive disease. Two year mucosal and local nodal control rates were 97.1% (95% confidence interval 91.4-100) and 89.8% (78.4-100), respectively. One mucosal primary was detected 7.3 months after TM-IMRT and three patients died from recurrent/metastatic squamous cell carcinoma of the head and neck. Twelve patients (33%) developed grade 3 (Late Effects in Normal Tissue-Subjective, Objective, Management and Analytical; LENT-SOMA) dysphagia with a 1 year enteric tube feeding rate of 2.7%. The high-grade subjective xerostomia rate (LENT-SOMA) at 24 months after IMRT was 15%. CONCLUSIONS: At a median follow-up of 36.1 months, the use of TM-IMRT was associated with good local control. Toxicity was comparable with previously reported TM-IMRT regimens encompassing similar mucosal volumes.
Authors: J A Dean; L C Welsh; K H Wong; A Aleksic; E Dunne; M R Islam; A Patel; P Patel; I Petkar; I Phillips; J Sham; U Schick; K L Newbold; S A Bhide; K J Harrington; C M Nutting; S L Gulliford Journal: Clin Oncol (R Coll Radiol) Date: 2017-01-03 Impact factor: 4.126
Authors: Mona Kamal; Abdallah S R Mohamed; Clifton David Fuller; Erich M Sturgis; Faye M Johnson; William H Morrison; G Brandon Gunn; Katherine A Hutcheson; Jack Phan; Stefania Volpe; Sweet Ping Ng; Jae Phan; Carlos Cardenas; Renata Ferrarotto; Steven J Frank; David I Rosenthal; Adam S Garden Journal: Adv Radiat Oncol Date: 2020-05-15
Authors: Jamie A Dean; Kee H Wong; Hiram Gay; Liam C Welsh; Ann-Britt Jones; Ulrike Schick; Jung Hun Oh; Aditya Apte; Kate L Newbold; Shreerang A Bhide; Kevin J Harrington; Joseph O Deasy; Christopher M Nutting; Sarah L Gulliford Journal: Int J Radiat Oncol Biol Phys Date: 2016-08-22 Impact factor: 7.038
Authors: Alexander D Sherry; Dario Pasalic; G Brandon Gunn; C David Fuller; Jack Phan; David I Rosenthal; William H Morrison; Erich M Sturgis; Neil D Gross; Maura L Gillison; Renata Ferrarotto; Adel K El-Naggar; Adam S Garden; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25